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Gene therapy of diseases like cystic fibrosis (CF) would consist in delivering a gene medicine 
towards the lungs via the respiratory tract into the target epithelial cells. Accordingly, poly-
functional nano-carriers are required in order to overcome the various successive barriers of 
such complex environment, among which the airway colonization with bacterial strains. In 
this work, the antibacterial effectiveness of a series of cationic lipids is investigated before 
evaluating its compatibility with gene transfer into human bronchial epithelial cells. Among 
the various compounds considered, some bearing a trimethyl-arsonium headgroup 
demonstrate very potent biocide effects towards clinically relevant bacterial strains. Contrary 
to cationic lipids exhibiting no or insufficient antibacterial potency, arsonium-containing 
lipophosphoramides can simultaneously inhibit bacteria while delivering DNA into eukaryotic 
cells, as efficiently and safely as in absence of bacteria. Moreover, such vectors can 
demonstrate antibacterial activity in vitro while retaining high gene transfection efficiency to 
the nasal epithelium as well as to the lungs in mice in vivo. Arsonium-containing amphiphiles 
are the first synthetic compounds shown able to achieve efficient gene delivery in presence of 
bacteria, a property particularly suitable for gene therapy strategies under infected conditions 








Gene therapy for the treatment of inherited diseases like CF is an active field of research. 
Several pre-clinical and clinical gene therapy studies using viral or non-viral vectors have 
been performed; they have pointed out the need of nucleic acid carriers displaying improved 
efficacy together with reduced side-effects.[1] Thus, smart and sophisticated systems continue 
to be developed, combining multiple properties in order to overcome the various successive 
barriers which hamper gene delivery.[2] When considering lung gene therapy for CF, a 
particular hurdle concerns the environmental colonization by multiple, usually multi-resistant, 
bacterial strains.[3] Indeed, it is well-established that chronic pulmonary infections affect the 
gene transfection mediated by viral or non-viral vectors.[4] 
Over the last several years, numerous studies have reported diverse non-viral gene delivery 
systems capable of delivering DNA to the lungs in vivo. Among these synthetic vectors, 
cationic lipids are particularly attractive as it is possible to design and synthesize a great 
variety of reagents combining multiple favorable features such as simplicity of use, relatively 
high transfection activity, biodegradability, etc.[5] We ourselves have developed various 
phosphonolipids, lipophosphoramides, and lipothiophosphoramides with a view to reach the 
“best” compromise between efficacy and side-effects to the target cells or animals. A series of 
chemical variations were undertaken that involved the different parts constituting the basic 
chemical structure of cationic lipids, notably the cationic headgroup[6] and the spacer 
moiety.[7] The replacement of the trimethyl-ammonium by a trimethyl-phosphonium or -
arsonium led to derivatives exhibiting significantly lower cytotoxicity.[6a,b] Recently, the 
modulation of fatty acid chains was investigated in the lipophosphoramide series; replacing 
oleyl[8] by linoleyl[9] or phytanyl[10] chains led to successive improvement regarding both 
transfection efficiency and biocompatibility in mice in vivo. Of note, all these derivatives 
were evaluated considering mainly their ability to deliver genes into mammalian cells. 
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However, other studies reported that cationic amphiphiles may also display some antibacterial 
activities.[11] Kichler et al. showed that cationic steroid antibiotics, which demonstrate DNA 
delivery properties, may also possess significant antibacterial potencies.[12] Lipidic derivatives 
of aminoglycosides have also been developed for gene transfection considering that these 
widely-used antibiotics bind nucleic acids with high affinity; while showing remarkable 
abilities as vehicles for the delivery of DNA[13] or RNA,[14] these compounds may also retain 
some antibacterial properties.[15] More recently, it was reported that a series of cationic sterol 
lipids can demonstrate some gene transfer and bactericidal activities.[16] It is noteworthy here 
that, in all these previous reports, the transfection properties and the antibacterial effects were 
investigated in independent experiments.  
In the current study, we wonder whether one single compound could achieve at the 
same time (i) biocide effects towards bacterial cells together with (ii) efficient and safe gene 
transfer into human bronchial epithelial cells, under experimental conditions mimicking gene 
delivery within airways infected with a virulent antibiotic resistant strain (Figure 1). In order 
to address this question, we first investigate the antibacterial activity of numerous cationic 
lipids that were only used until now as transfection reagents; this series included a 
representative panel of our own cationic lipids further completed with some novel derivatives 
herein synthesized. The screening performed aimed at (i) unveiling structure−activity 
relationships and (ii) identifying compounds active at concentrations compatible with gene 
transfection experiments. Next, in vitro cell culture assays were performed to determine the 
ability of some selected compounds to display both antibacterial and gene transfection 
activities, either sequentially (i.e. the first then the second) or simultaneously (i.e., 
concomitantly, in one pot). Finally, investigations were conducted in mice in order to test 
whether the observations raised from in vitro studies could be further extended to in vivo 
experimental settings.  
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2. Results and Discussion 
The chemical structure of the main synthetic phospholipids included in this study is reported 
in Table 1 (see also Figure S1). The synthesis pathway used to obtain 1, 6, 8, and 11 is 
summarized in Figure 2, the protocols being detailed in the Experimental Section. In addition, 
the crystal structure of compound 6 is described in Figure S2. These cationic lipids were 
formulated as liposomal solutions, their size and charge being on average ~200 nm and ~50 
mV, respectively (Table S1). 
 
2.1. Antibacterial Effectiveness of a Series of Cationic Lipids 
All cationic liposomes were first evaluated as regards their biocide effect towards a series of 
Gram-positive and Gram-negative bacterial strains: three S. aureus (the laboratory strain 
RN4220,[17] the clinical strain Newman,[18] and the clinical methicillin-resistant S. aureus 
(MRSA) strain N315[19]), one E. coli (the laboratory strain MG1655[20]) and two P. 
aeruginosa (the clinical strains PA130709 and PA240709, each isolated from the sputum of a 
CF patient). Of note, these strains were chosen considering that they can be part of the 
microbiota colonizing the lungs of CF patients.[21] Some of them are resistant to numerous 
antibiotics (Table S2). In order to determine susceptibilities to cationic lipids, a liquid broth 
micro-dilution assay was employed as previously reported by ourselves[22] and others.[23] 
Table 1 summarizes the antibacterial activities found; the values reported herein correspond to 
minimal bactericidal concentrations (MBC), rather than minimal inhibitory concentrations 
(MIC), since, in each case, no bacterial growth occurred when aliquots of corresponding 
liquid cultures were spread onto non-selective nutritive agar plates. Whereas most derivatives 
are completely ineffective (i.e., MBC > 200 µм), some others display remarkable bactericidal 
activities, the lowest MBC being close to 1 µм. These activities are mostly measured using S. 
aureus strains and, in some cases, the E. coli strain. Notably, 1, 2, and 3 retain their activities 
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against six different S. aureus strains (Table 1 and data not shown), especially towards one 
MRSA (N315[19]). The importance of this finding is further emphasized when considering 
previous similar reports.[24] For comparative purposes, the activities of benchmark compounds 
were determined under the same experimental conditions. First, well-known cationic 
transfection reagents such as Lipofectamine (LFM; Invitrogen), bis(guanidinium)-tren 
cholesterol (BGTC),[25] or poly(ethylenimine) (PEI)[26] do not exhibit any antibacterial activity. 
The silver carbene 14 is active but mostly against Gram-negative strains, in agreement with 
literature results.[23] Finally, three commonly used antibiotics (kanamycin, ampicillin, and 
tetracyclin) are either totally ineffective (MBC> 200 µм) or active with MBC ranging from 1 
up to 200 µм. Taken together, these results highlight the antibacterial potential of several 
cationic lipophosphoramides showing that: (i) they are active at low concentrations (close to 
the MBC of the most efficient antibiotics tested); (ii) their MBC are in the same range of 
concentrations as those typically used for gene transfection (between 1 to 200 µм); (iii) 
importantly, in contrast to antibiotics, their activity appears independent of the antibiotic 
resistance profile as well as the virulence potential of the strains. 
 
2.2. Structure–Antibacterial Activity Relationships 
The various cationic lipids investigated exhibiting very different MBC, their chemical 
structure thus directly impact on their antibacterial activity. First, the polar headgroup is an 
obvious key parameter. Indeed, only the cationic lipids possessing a trimethyl-arsonium (1-5) 
or a trimethyl-phosphonium (12) headgroup can display such an activity; a trimethyl-
ammonium polar head is on contrary clearly detrimental as observed when comparing the 
MBC of the 1/8, 3/9 and 4/10 couples. The amphiphiles possessing a trimethyl-arsonium 
demonstrate the lowest MBC, being clearly more potent than their trimethyl-phosphonium 
analogs (3 versus 12). This might be ascribed to the size and the geometry of the cationic 
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polar head as these parameters can determine the strength of any dipolar interaction in which 
the headgroup might be involved (the trimethyl-arsonium polar head being indeed bigger than 
the trimethyl-phosphonium which is itself bigger than the trimethyl-ammonium[27]). A similar 
correlation was recently observed when comparing the transfection activity of arsonium-
containing cationic lipids with that of ammonium analogs.[27,28] Of note, the incorporation of 
another type of cationic moiety (guanidinium in 11) is detrimental for the bactericidal effect. 
However, it must be noted that the use of a trimethyl-arsonium headgroup, although necessary, 
is not sufficient to design an efficient antibacterial compound. Indeed, the arsonium-
containing lipophosphoramide 6, which has two short ethyl chains, is completely devoid of 
any antibacterial activity.  
Accordingly, the structural features of the hydrophobic domain also determine the 
level of antibacterial efficacy; indeed, lipophosphoramides which only vary according to this 
chemical part displayed quite different activities. It is noteworthy here that the antibacterial 
potency of free fatty acids of various chain lengths and with different unsaturation degrees 
was reported earlier; they have been shown to be mainly effective against Gram-positive 
strains.[29] With regard to the cationic lipids investigated, it is noticeable that they all contain 
two aliphatic chains but, unlike free fatty acids, these chains are linked together to a cationic 
headgroup. Our results show some consistencies with those reports[29] as we observed that 2, 
an arsonium-containing lipophosphoramide bearing long di-unsaturated lipid chains (C18:2), 
was more potent than 3, its mono-unsaturated analogue (C18:1), which was itself better than 5, 
a fully saturated derivative (C18:0). Short saturated lipid chains (C14:0) can also greatly 
contribute to the antibacterial activity, depending on the polar headgroup and the linker they 
are associated with. Indeed, despite 1 and 8 are structurally close (they both incorporate two 
myristic chains and they only vary as regards their cationic group), they were highly efficient 
or completely ineffective, respectively. Altogether, this suggests that, unlike free fatty acids, 
  Submitted to  
8 
 
the lipid chains in cationic lipids may not be sufficient to provide, by themselves, an 
antibacterial potency; however, they are clearly essential and their chemical structure greatly 
modulate the antibacterial effectiveness.  
Finally, the spacer moiety, which links together the polar headgroup and the lipid 
domain, also impacts the antibacterial potency depending on its chemical structure. Of note, 1 
and 4 are two structural analogues that only differ as regards their linker: P(O)C phosphonate 
versus P(O)N phosphoramide, respectively. As shown in Table 1, 4 was identified as a potent 
antibacterial compound against Gram-positive strains but, in all cases, it displayed MBC 
higher than those of 1; when considering E. coli (a Gram-negative strain), 4 was inefficient 
(MBC > 200 µм) while 1 demonstrated the lowest MBC reached using this strain. The 
importance of the spacer moiety regarding the antibacterial potency is further evidenced when 
comparing the activity of the lipophosphoramide 3 with that of the lipothiophosphoramide 
7.[30] In our tests, these two derivatives interacted very differently with bacteria, as 3 
demonstrated some antibacterial activities whereas 7 did not. Of note, changing the P(O)N 
functional group to a P(S)N decreases the polarity of the spacer moiety and, consequently, it 
extends the hydrophobic domain of the cationic lipid. In addition, it is likely that the lower 
polarity of the P(S)N functional group does not allow to form hydrogen bond networks as 
strong as the P(O)N. As observed when considering 6 at solid state (Figure S2), the P(O)N 
linkage should participate, via hydrogen bonds, in intermolecular interactions between 
neighbouring lipophosphoramide entities, thus contributing to supramolecular organization as 
micelles or liposomes.  
Overall, our results evidence that the whole chemical architecture of arsonium-
containing lipophosphoramides (i.e., the combination of a trimethyl-arsonium headgroup, a 
phosphoramide spacer, and two short saturated or long unsaturated lipid chains) plays a 
critical role in their antibacterial ability. Interestingly, these results highlight that optimizing 
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the design of our cationic lipids for enhanced gene transfer activity led to a concomitant 
optimisation of their antibacterial potency. 
 
2.3. Further Characterizations of Antibacterial Properties 
Additional experiments unveiled deeper insights into the antibacterial properties of arsonium-
containing cationic lipids (compounds hereafter termed arsenolipids). First, we observed that 
bactericidal effects were not immediate but delayed in time; indeed, they were preceded by 
bacterial growth inhibitions, i.e., arsenolipids were first bacteriostatic before being 
bactericidal (Figure 3). The cationic lipid dose and its exposure time with bacteria determined 
a balance between bacteriostatic and bactericidal effects. Schematically, for one given 
cationic lipid, the higher the dose, the shorter the time required to kill bacteria. As an example, 
a complete bactericidal effect was obtained after 2 h of incubation with 100 µg mL-1 of 2 
whereas the MBC dropped down to 40 µg mL-1 for an incubation time of 15 h ½; furthermore, 
a minimum of 20 µg mL-1 of 2 was required to obtain a bacteriostatic effect, a dose which 
became bactericidal after an incubation time as long as 32 h. Such antibacterial properties 
suggest that arsenolipids are not “detergent-like biocides” but, more likely, they might act 
through the alteration of vital cellular pathways. Additionally, the effect of the bacterial 
inoculum size was also considered as it determines the antibacterial potencies.[31] Not 
surprisingly, the higher the starting inoculum, the higher the cationic lipid dose required to 
obtain a complete bactericidal effect (Figure 4). However, we found that a potent arsenolipid 
is able to keep bacteriostatic/bactericidal effects up to very high bacterial densities. For 
instance, after 23 h at 37 °C, 5 µм of 2 were sufficient to kill all bacteria when ~103 colony 
forming unit (CFU) mL-1 were initially used, whereas the MBC was 75 µм when starting with 
~109 CFU mL-1, i.e., the MBC was multiplied by only 15 when the inoculum was multiplied 
by 106 (Figure 4). These results clearly emphasize the robustness of the antibacterial effects 
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mediated by the most potent arsenolipids. Importantly, they also indicate that such activities 
can persist regardless of the bacterial growth state (whether bacteria actively divide or not), a 
crucial property when expecting therapeutic efficacy at infectious sites where bacteria are not 
actively growing, especially in vivo (e.g., as in tuberculosis). The emergence of drug 
resistances in bacteria towards conventional antibiotics is a major public-health concern. In 
order to investigate whether or not arsonium-containing cationic lipids might select for drug-
resistant isolates, the MRSA strain N315 was cultivated for serial passages on half-MIC of 2, 
MIC values being re-evaluated every 24 h. As a positive control, the antibiotic norfloxacin 
was evaluated in parallel in the same way (Figure S3). While a strong increase in MIC of 
norfloxacin was already detected after 3 passages (reaching more than 20-fold the initial value 
after 10 days), the susceptibility of bacteria towards 2 did not change, even after 10 passages. 
This supports that arsonium-containing cationic lipids should not participate in the 
development of drug-resistant strains. 
 
2.4. Combined Antibacterial and Eukaryotic Cell Transfection Assays 
On the basis of these findings, in vitro experiments combining antibacterial and transfection 
assays were conducted thereafter. For these tests, cationic lipids were first mixed with a 
luciferase reporter plasmid DNA (pDNA) in order to obtain complexes called lipoplexes. 
Luciferase gene expression was used to report not only eukaryotic cell transfection efficiency 
but also cellular integrity (assuming that impaired cells should not be able to achieve “normal” 
gene expression). A sequential assay was first worked out in a view to easily and clearly 
determine, step by step, the ability of one single compound to display (1) antibacterial activity 
(2) DNA compaction and protection and finally (3) gene transfer into human bronchial 
epithelial cells. Next, a simultaneous assay was performed: one candidate compound was used 
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to test whether antibacterial and gene transfer activities could be obtained at the same time in 
one pot, under experimental conditions approaching real in vivo settings (Figure 1). 
 
2.4.1. Sequential Assay 
As we have previously demonstrated the high transfection efficiency of several cationic lipids 
herein identified as potent antibacterials, we next wondered whether such compounds could 
achieve these two tasks sequentially: the antibacterial activity of lipoplexes was first 
determined (via incubation with bacteria for 24 h) before evaluating the transfection 
efficiency of these mixtures (by introducing them directly into the culture medium of 
eukaryotic cells). These experiments were carried out using 1, 2 and 3; the results obtained 
using 2 are shown in Figure 5 (the complete set of results is available in Figures S5 and S6). 
Lipoplexes were prepared at different charge ratios (CR, +/-; which is the ratio of the positive 
charges provided by the vector polar headgroup to the negative charges provided by the DNA 
phosphates), from 0.5 to 4.0. As shown in Figure 5A, 2-based lipoplexes displayed 
antibacterial activity as did corresponding liposomes, the MBC estimated here in 10% serum 
supplemented medium being similar to those previously measured in Luria Broth (LB; Table 
1). Under identical conditions, LFM still didn’t show any antibacterial activity. Panel B 
illustrates the compaction and protection of pDNA. When mixed with 2, a full compaction 
was observed from CR 2; interestingly, at lower CR, pDNA was not deteriorated (despite it 
was only partially condensed). On the contrary, DNA mixed (or not) with LFM was degraded, 
as a consequence of bacterial growth (Figure S4). The addition of dextran sulfate further 
verified that the antibacterial activity of 2-based lipoplexes can be obtained together with an 
efficient pDNA compaction and protection (Figure 5B and Figure S5). Finally, after 24 h at 
37 °C, the transfection activity of “lipoplexes + bacteria” mixtures was examined: 2-based 
lipoplexes were still able to transfect eukaryotic cells in vitro; their transfection efficiency was 
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actually the same as those measured with control lipoplexes (that were not mixed with any 
bacteria), even at CR½. In the comparative experiment using LFM, the transfection efficiency 
was lost, likely due to the pDNA deterioration by bacteria (Figure 5C and Figure S6). Thus, 
one single arsenolipid can sequentially exert antibacterial activities and subsequently mediate 
gene transfer into eukaryotic cells, contrary to other cationic lipids devoid of any antibacterial 
activity such as LFM (Figure 5) or 10 (data not shown). 
 
2.4.2. Simultaneous Assay 
Considering that 2 allows obtaining the best compromise between antibacterial activity 
and transfection efficiency, it was used for further in vitro evaluations in which 
prokaryotic and eukaryotic cells were cultured together, i.e., in one pot. Of note, the 
highly virulent clinical strain N315[19] was employed here. The luciferase activity (which 
reports the transfection efficiency) on one hand and the adenylate kinase activity (which 
measures not only cellular injuries but also bacterial growth; see Figure S7) on the other 
hand were determined at different time points of this experiment. Figure 6 shows the 
results obtained with 2 or LFM when mixed with a pDNA at CR10; the results obtained 
using lipoplexes formed at 6 other CR (ranging from 4 to 9) are provided in Figure S8. 
Regarding the evaluations performed using LFM, the transfection efficiency progressively 
increased over time when bacteria were absent; in contrast, under conditions wi th bacteria, 
it first increased up to 21 h then no longer evolved during the rest of the experiment 
(Figure 6B). Such a transfection profile was obviously related to the progression of the 
infection, as the transfection inhibition was coincidental with the bacterial growth 
exponential phase (Figure 6A). These observations were roughly the same whatever the 
CR considered. Thus, despite LFM was a potent reagent for transfecting cells under sterile 
conditions, its inability to prevent bacterial growth clearly hampered its transfection 
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efficiency under infected conditions. This might result both from pDNA degradation and 
cellular injuries caused by the virulent bacteria used here. On contrary, 2-based lipoplexes 
formed at CR10 mediated potent antibacterial activity (Figure 6A) together with very 
similar transfection profiles in the two compared experimental settings (with or without 
bacteria; Figure 6B). It is noteworthy that, at lower CR, 2 displayed either no or little 
antibacterial activity (CR4 to 6) or transient bacteriostatic effects (CR7 to 9); however, 
from CR5 and above, the transfection efficiencies measured at each time point in sterile 
versus contaminated conditions were of the same order of magnitude (Figure S8). Thus, in 
presence of bacteria, 2 is able to retain high transfection efficiency, even at doses that did 
not mediate any strong antibacterial effect. This might result from a protective effect 
towards both pDNA and eukaryotic cells against any bacterial-induced damages. 
Altogether, these findings emphasize that, in an infected environment, gene delivery can 
be more efficiently achieved by using a vector endowed with some antibacterial activity.  
 
2.5. In vivo Investigations 
Finally, we wondered whether the compatibility between the antibacterial and transfection 
activities of arsonium-containing lipophosphoramides could be further evidenced in an 
experimental setting using animals. Indeed, these reagents were evaluated earlier for in vivo 
gene transfer in mice, where they demonstrated high efficiencies together with acceptable 
toxicities for the host.[8,9,10] It is noteworthy that, in such applications, cationic lipids are used 
at concentrations (typically several hundred µм) higher than those identified here as 
bactericidal. In an attempt to clearly address the potential of a dual-effectiveness in the 
context of in vivo gene delivery, the antibacterial and transfection activities of an arsonium-
containing lipophosphoramide were studied sequentially: 2-based lipoplexes were first 
incubated in vitro with bacteria for several hours before evaluating their in vivo transfection 
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efficiency. We assume that such an experimental setting mimick, at least in part, the 
sequential steps of in vivo gene delivery in a contaminated environment, as lipoplexes would 
first mix with bacteria before they can reach their target cells. First of all, we observed that 2-
based lipoplexes were still able to efficiently inhibit bacterial growth and protect DNA; 
indeed, after several hours at 37 °C, a complete bactericidal effect was obtained and the DNA 
entrapped within the lipoplexes remained intact (not shown). Next, lipoplexes were 
administered in mice via either systemic or local delivery routes; non-invasive in vivo 
bioluminescence imaging revealed that luciferase activity was detectable around the lung area 
and from the nostril of animals, respectively (Figure 7A). Importantly, the luminescence 
signals collected were of the same order of magnitude whether lipoplexes were initially mixed 
with bacteria or not (Figure 7B). Thus, in presence of bacteria, 2-based lipoplexes can exhibit 
antibacterial activities while still retaining the required properties for efficient in vivo 
transfection, an important finding when considering lung gene therapy for diseases like CF. 
Ongoing in vivo experiments using animal models for septicaemia or chronic pulmonary 
infection will allow to further investigate the usefulness of arsonium-containing cationic lipids.  
 
3. Conclusions 
In summary, we have evidenced a particular class of cationic lipids, arsonium-containing 
lipophosphoramides, as efficient and robust antibacterial agents effective against Gram-
positive, including multi-resistant, virulent clinical strains. The most potent compounds being 
active at relatively low concentrations, a balance can be found between (i) a selective biocide 
effect towards bacterial cells and (ii) an efficient and safe gene transfer into eukaryotic cells, 
leading to transgene expression. To the best of our knowledge, this is the first time that such a 
double simultaneous effect is demonstrated for one given compound. Such poly-functional 
nano-carriers may be suitable for a variety of applications. (i) For instance, they may help 
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preventing or fighting bacterial infections in various biological contexts; notably, they could 
be used to eradicate intracellular bacteria. (ii) They may also be useful for gene transfection 
studies under conditions where conventional antibiotics cannot be used. (iii) Finally, our 
findings further evidence the potential of arsenolipids for non-viral gene therapy in situations 
where bacterial infections might not be fully eradicated prior to gene transfer. Indeed, 
compounds able to retain their transfection activity under infected conditions (as 
demonstrated herein, in vitro as well in vivo) might be particularly suitable for gene therapy 
strategies in complex environments such as within the infected airways of CF patients. At 
present, arsonium-containing lipophosphoramides are evaluated in cocktails with the aim to 
obtain broader antibacterial spectrum. In conclusion, future sophisticated gene delivery 
systems may incorporate arsenolipids as “double-edged” active components for antibacterial 
as well as gene transfer applications. 
 
4. Experimental Section 
Chemicals and reagents: The cationic lipids 2 (BSV4),[9] 3 (KLN47),[8] 4 (BSV98),[32] 5 
(BSV82),[33] 7 (BSV21),[30] 9 (BSV36),[32] and 10 (GLB43),[34] as well as the silver complex 
12[23] were synthesised following reported methodologies. The other cationic lipids were 
synthesised as reported below. Lipofectamine (a commercial liposomal formulation of 
DOSPA/DOPE 3/1, w/w) was obtained from Invitrogen. DOPE (1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine) and PE-PEG5000 (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-5000]) were purchased from Avanti Polar Lipids.  
Chemical synthesis: The cationic lipids were purified by flash chromatography 
(GRACE REVELERIS Flash Chromatography System) equipped with UV and DLS detectors 
allowing to attest the high purity (> 95%) of the purified compounds. These compounds were 
characterized by NMR (1H, 31P, 13C), including HMBC and HMQC experiments, and also by 
high-resolution mass spectrometry (HRMS). Pertinent spectroscopic and analytical data are 
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given below. Caution: care must be taken when handling trimethyl-arsine. All related 
experiments should be performed in a fume hood in a room that may be well-ventilated. 
Synthesis of O,O-Ditetradecyl-N-(2-N’,N’-dimethylaminoethyl)phosphoramide 14: To 
ditetradecylphosphite (1.0 g, 2.1 mmol) and N,N-dimethylaminoethylenediamine (205 mg, 2.3 
mmol) and bromotrichloromethane (230 µL, 2.3 mmol) in anhydrous dichloromethane (10 
mL), at 0 °C, di-isopropylethylamine (DIPEA) (404 µL, 2.3 mmol) was slowly added. The 
reaction was further stirred for 1 h at 0 °C then 5 h at room temperature (RT). Solvent was 
evaporated in vacuo and the residue filtered on Celite. The filtrate was concentrated and 
purified by flash column chromatography on silica gel (CH2Cl2/MeOH, 9/1) to produce 14 as 
a viscous oil (1.1 g, 85% yield). 1H NMR (CDCl3) δ 0.83 (t, 3JHH = 7.2 Hz, 6H, CH3-), 1.23 
(m, 44H, -CH2-), 1.59 (m, 4H, -CH2-), 2.26 (s, 6H), 2.40 (t, 3JHH = 5.7 Hz, 2H, -CH2-N-), 2.98 
(m, 3JHH = 5.7 Hz, 2H, -CH2-NH), 3.25 (bs, 1H, -NH-), 3.95 (m, 3JHH ~ 3JHP = 6.5 Hz, 4H, -
CH2-O-). 13C NMR (CDCl3) δ 14.4, 23.0, 25.9, 29.6-30.8, 32.3, 38.9, 45.4, 59.9 and 66.7. 31P 
NMR (CDCl3) δ 9.8. HRMS (MALDI-TOF) m/z calcd for C32H69N2O3P [(M+H)+] 561.512; 
found 561.502. 
Synthesis of O,O-Ditetradecyl-N-(2-trimethylaminoethyl)phosphoramide 8 (BSV61): To 
compound 14 (500 mg, 0.9 mmol) in anhydrous dichloromethane (10 mL) was added 
methyliodide (640 mg, 4.5 mmol) and the reaction was stirred overnight at RT. The crude was 
concentrated and the residue was purified by flash column chromatography on silica gel 
(CH2Cl2/MeOH, 9/1) to produce 8 as a colourless solid (582 mg, 92% yield). 1H NMR 
(CDCl3) δ 0.86 (t, 3JHH = 7.2 Hz, 6H, CH3-), 1.24 (m, 44H, -CH2-), 1.65 (m, 4H, -CH2-), 3.47 
(s, 9H), 3.55 (m, 3JHH = 5.6 Hz, 2H, -CH2-N), 3.87 (t, 3JHH = 5.6 Hz, 2H, -CH2-NH), 3.99 (m, 
3JHH ~ 3JHP = 6.5 Hz, 4H, -CH2-O-), 4.44 (bs, 1H, -NH-). 13C NMR (CDCl3) δ 14.4, 23.0, 25.9, 
29.6-30.8, 32.3, 35.4, 54.1, 59.9 and 66.9. 31P NMR (CDCl3) δ 8.7. HRMS (MALDI-TOF) 
m/z calcd for C33H72N2IO3P [(M+-I)] 575.528; found 575.531. 
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Synthesis of O,O-Ditetradecyl-N-(2-aminoethyl)phosphoramide 15: To 
ditetradecylphosphite (1.30 g, 2.7 mmol), ethylenediamine (1.6 g, 27.0 mmol) in anhydrous 
dichloromethane (10 mL) at 0 °C was added dropwise bromotrichloromethane (300 µL, 2.7 
mmol). The reaction was stirred for 1 h at 0 °C then 5 h at RT. The crude was concentrated 
and the residue was taken up in dichloromethane, washed three times with water, brine, dried 
with MgSO4, filtered and concentrated to furnish 15 as a viscous oil (1.2 g, 85% yield). The 
oily product was engaged in the next step without further purification. 1H NMR (CDCl3) δ 
0.83 (t, 3JHH = 7.2 Hz, 6H, CH3-), 1.23 (m, 44H, -CH2-), 1.59 (m, 4H, -CH2-), 2.78 (t, 3JHH = 
5.7 Hz, 2H, -CH2-NH2), 2.97 (m, 3JHH = 5.7 Hz, 2H, -CH2-NH), 3.25 (bs, 1H, -NH-), 3.95 (m, 
3JHH ~ 3JHP = 6.5 Hz, 4H, -CH2-O-). 13C NMR (CDCl3) δ 14.4, 23.0, 25.9, 29.6-30.7, 32.3, 
43.2, 44.1 and 66.8. 31P NMR (CDCl3) δ 9.8. HRMS (MALDI-TOF) m/z calcd for 
C30H65N2O3P [(M+H)+] 533.481; found 533.472. 
Synthesis of O,O-Ditetradecyl-N-(2-guanidinoethyl)phosphoramide 11 (BSV62): 
Compound 15 (500 mg, 0.9 mmol) and 1H-pyrazole-1-carboxamidine hydrochloride (151 mg, 
1.0 mmol) were combined in absolute ethanol. DIPEA (181 µL, 1.0 mmol) was added and the 
reaction was heated to reflux overnight. Solvent was evaporated in vacuo, and the residue was 
taken up in chloroform, washed with water and brine, dried with MgSO4, filtered and 
concentrated to furnish 11 as a viscous oil (484 mg, 88% yield). 1H NMR (CDCl3) δ 0.87 (t, 
3JHH = 7.2 Hz, 6H, CH3-), 1.29 (m, 44H, -CH2-), 1.61 (m, 4H, -CH2-), 3.06 (m, 2H, -CH2-
NH2), 3.36 (m, 2H, -CH2-NH), 3.93 (m, 3JHH ~ 3JHP = 6.5 Hz, 4H, -CH2-O-), 4.65 (bs, 1H, -
NH-), 7.20 (bs, 2H, -NH2), 7.88 (bs, 1H, ═NH). 13C NMR (CDCl3) δ 14.5, 23.0, 26.0, 29.7-
30.8, 32.3, 41.1, 43.1, 67.4 and 158.7. 31P NMR (CDCl3) δ 10.6. HRMS (MALDI-TOF) m/z 
calcd for C31H68ClN4O3P [(M+- Cl)] 575.502; found 575.400. 
Synthesis of O,O-Ditetradecyl-N-(2-bromoethyl)phosphoramide 16a: To ditetradecyl-
phosphite (500 mg, 1.1 mmol), 2-bromoethylamine bromohydrate (237 mg, 1.2 mmol) and 
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bromotrichloromethane (230 µL, 2.3 mmol) in anhydrous dichloromethane (5 mL) at 0 °C, 
was slowly added DIPEA (404 µL, 2.3 mmol). The reaction was stirred for 1 h at 0 °C then 3 
h at RT. Solvent was evaporated in vacuo, and ether was added (10 mL). The precipitate was 
removed by filtration on Celite. The filtrate was concentrated to produce 16a as a viscous oil 
(590 mg, 90% yield) which was engaged in the next step without further purification. 1H 
NMR (CDCl3) δ 0.77 (t, 3JHH = 7.2 Hz, 6H, CH3-), 1.16 (m, 44H, -CH2-), 1.56 (m, 4H, -CH2-), 
3.18 (m, 3JHH = 6.4 Hz, 2H, -CH2-NH), 3.32 (t, 3JHH = 6.4 Hz, 2H, -CH2-Br), 3.71 (bs, 1H, -
NH-), 3.87 (m, 3JHH ~ 3JHP = 6.5 Hz, 4H, -CH2-O-). 13C NMR (CDCl3) δ 14.3, 21.6, 26.2, 
29.5-30.7, 32.2, 33.7, 43.4 and 66.7. 31P NMR (CDCl3) δ 9.6. HRMS (MALDI-TOF) m/z 
calcd for C30H63BrNO3P [(M+)] 595.373; found 595.536. 
Synthesis of O,O-Diethyl-N-(2-bromoethyl)phosphoramide 16b: To diethylphosphite 
(1.0 g, 7.2 mmol), 2-bromoethylamine bromohydrate (1.6 g, 8.0 mmol) and 
bromotrichloromethane (230 µL, 16.0 mmol) in anhydrous dichloromethane (10 mL) at 0 °C, 
was slowly added DIPEA (4.3 mL, 16.0 mmol). The reaction was stirred for 1 h at 0 °C then 3 
h at RT. Solvent was evaporated in vacuo, and ether was added (20 mL). The precipitate was 
removed by filtration on Celite. The filtrate was concentrated to produce 16b as a viscous oil 
(1.8 g, 95% yield). The oily product was engaged in the next step without further purification. 
1H NMR (CDCl3) δ 1.30 (t, 3JHH = 7.2 Hz, 6H, CH3-), 3.11 (bs, 1H, -NH-), 3.30 (m, 3JHH = 6.0 
Hz, 2H, -CH2-NH), 3.46 (t, 3JHH = 6.0 Hz, 2H, -CH2-Br), 4.03 (m, 3JHH ~ 3JHP = 6.5 Hz, 4H, -
CH2-O-). 13C NMR (CDCl3) δ 16.3, 33.4, 43.1, and 62.3. 31P NMR (CDCl3) δ 8.8. HRMS 
(MALDI-TOF) m/z calcd for C6H15BrNO3P [(M+H)+] 260.005; found 259.971. 
Synthesis of O,O-Ditetradecyl-N-(2-iodoethyl)phosphoramide 17a: Compound 16a (375 
mg, 6.8 mmol) and sodium iodide (1.4 g, 9.0 mmol) were combined in tetrahydrofurane (5 
mL). The solution was refluxed overnight. After cooling, the volatiles were removed in vacuo 
and ether (10 mL) was added. The solution was filtered on Celite to remove sodium bromide 
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and the filtrate was concentrated to furnish compound 17a as brown solid (331 mg, 82% 
yield) which was engaged in the next step without further purification. 1H NMR (CDCl3) δ 
0.83 (t, 3JHH = 7.2 Hz, 6H, CH3-), 1.23 (m, 44H), 1.63 (m, 4H, -CH2-), 3.19-3.22 (m, 4H, -
CH2-), 3.59 (bs, 1H, -NH-), 3.97 (m, 3JHH ~ 3JHP = 6.5 Hz, 4H, -CH2-O-). 13C NMR (CDCl3) δ 
6.9, 14.4, 21.7, 25.9, 29.5-33.2, 44.2, and 66.9. 31P NMR (CDCl3) 8.5. HRMS (MALDI-TOF) 
m/z calcd for C30H63INO3P [(M+H)+] 644.367; found 644.356. 
Synthesis of O,O-Diethyl-N-(2-iodoethyl)phosphoramide 17b: Compound 16b (1.8 g, 
6.8 mmol) and sodium iodide (1.4 g, 9.0 mmol) were combined in tetrahydrofurane (20 mL). 
The solution was refluxed overnight. After cooling, the volatiles were removed in vacuo and 
ether (20 mL) was added. The solution was filtered on Celite to remove sodium bromide and 
the filtrate was concentrated to furnish compound 16b as a viscous oil (1.5 g, 72% yield) 
which was engaged in the next step without further purification. 1H NMR (CDCl3) δ 1.25 (t, 
3JHH = 7.2 Hz, 6H, CH3-), 3.12 (bs, 1H, -NH-), 3.30 (m, 3JHH = 6.0 Hz, 2H, -CH2-NH), 3.36 
(m, 3JHH = 6.0 Hz, 2H, -CH2-I), 4.10 (m, 3JHH ~ 3JHP = 6.5 Hz, 4H, -CH2-O-). 13C NMR 
(CDCl3) δ 6.9, 16.4, 43.9 and 62.9. 31P NMR (CDCl3) 8.6. HRMS (MALDI-TOF) m/z calcd 
for C6H15INO3P [(M+H)+] 307.991; found 307.958. 
Synthesis of Ditetradecylphosphatidyl-2-aminoethyltrimethylarsonium Iodide 1 
(BSV77): Trimethylarsine (186 mg, 1.6 mmol) was added to a solution of compound 17a (500 
mg, 0.8 mmol) in anhydrous tetrahydrofuran (1 mL) placed in a Schlenk tube equipped with 
an efficient reflux condenser (-20 °C). The solution was placed in an oil bath and heated at 
60 °C for 48 h. The volatiles were removed in vacuo. The residue was dissolved in 
chloroform (2 mL) and purified by flash chromatography on silica gel (CH2Cl2/MeOH, 9/1) to 
produce compound 1 as a colourless solid (446 mg, 73% yield). 1H NMR (400 MHz, CDCl3): 
δ 0.88 (t, 6H, 3JHH = 7.2 Hz, 6H, CH3-), 1.26 (m, 44H), 1.66 (m, 4H, -CH2-), 2.23 (s, 9H), 3.15 
(t, 3JHH = 7.5 Hz, 2H, CH2-), 3.52 (m, 3JHH = 7.5 Hz, 2H, CH2-NH), 4.38 (m, 3JHH ~ 3JHP = 6.5 
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Hz, 4H, -CH2-O-), 4.48 (bs, 1H). 31P NMR (162 MHz, CDCl3) : 8.86. 13C NMR (300 MHz, 
CDCl3): 10.19, 14.45, 23.02, 25.93, 29.25-30.74, 32.26, 36.40, 67.50.HRMS (MALDI-TOF): 
m/z calcd. for C33H72AsINO3P [(M+-I)]: 636.446; found 636.488. 
Synthesis of Diethylphosphatidyl-2-aminoethyltrimethylarsonium Iodide 6 (BSV83): 
Trimethylarsine (586 mg, 5.0 mmol) was added to a solution of compound 17b (500 mg, 1.6 
mmol) in anhydrous tetrahydrofuran (1 mL) placed in a Schlenk tube equipped with an 
efficient reflux condenser (-20 °C). The solution was placed in an oil bath heated at 60 °C for 
48 h. The volatiles were removed in vacuo. The residue was dissolved in chloroform (2 mL) 
and purified by flash chromatography on silica gel (CH2Cl2/MeOH, 9/1) to produce 
compound 6 as a viscous oil (510 mg, 73% yield). 1H NMR(CDCl3) δ 1.18 (t, 3JHH = 7.2 Hz, 
6H, CH3-), 2.22 (s, 9H), 2.22 (s, 9H), 3.13 (t, 3JHH = 6.0 Hz, 2H, -CH2-), 3.48 (m, 2H, -CH2-), 
4.03 (dd, 3JHH ~ 3JHP = 6.6 Hz, 4H, -CH2-O-), 4.71 (m, 1H, -NH-). 13C NMR (CDCl3) δ 9.8, 
16.3, 18.6, 36.0 and 63.0. 31P (CDCl3) 8.9. HRMS (MALDI-TOF) m/z calcd for 
C9H24INO3PAs [(M+- I)] 300.070; found 300.036.  
Liposomal formulations: All cationic lipids (except 7) were formulated as liposomal 
solutions by the film hydration method, as previously described.[9] Lipids were mixed in 
chloroform then the solvent was evaporated. After drying, the film was hydrated for 12 h at 
4 °C in 500 mL of 10 mм Hepes buffer, pH 7.4. It was vortexed and sonicated for 15 min at 
20 °C at 37 kHz using an ultrasonic water bath (Bioblock Scientific). Liposomal solution of 7 
was obtained by the ethanolic injection method, as previously reported.[30] Finally, the mean 
diameter and zeta potential of the liposomes were determined by dynamic light scattering, 
using a 3,000 Zetasizer (Malvern Instruments) at 25 °C with a measuring angle of 90° to the 
incident beam. Liposomal formulations were kept at 4 °C until subsequent use. 
Bacterial strains: The various bacterial strains evaluated herein were as follows: three S. 
aureus (the laboratory strain RN4220,[17] and the clinical strains Newman[18] and MRSA 
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N315[19]), one E. coli (the laboratory strain MG1655[20]) and two P. aeruginosa (the clinical 
strains PA130709 and PA240709, that were isolated from CF patients during the course of 
this study). All bacterial routine handlings were conducted with Luria Bertani (LB) broth at 
37 °C. A complete antibiotic resistance profile was established for each strain (see Table S2). 
Plasmid DNA: Three different luciferase reporter pDNA were employed. For in vitro 
experiments, the pEGFP-Luc (6.4 Kb, Clontech) and the pGLuc (5.8 kb, New England 
Biolabs) were used. The pEGFP-Luc encodes a fusion of two reporter genes, the enhanced 
green fluorescent protein (EGFP; Abs/Em=488/507 nm) and the firefly Photinus pyralis 
luciferase; this pDNA allows evaluating the transfection activity via flow cytometry and 
luminometry. The pGLuc contains the “humanized” coding sequence for the secreted Gaussia 
Luciferase under the control of the cytomegalovirus promoter, for constitutive expression in 
mammalian cells; the gene transfer efficacy is readily detectable by dosing samples from the 
supernatant. For in vivo transfection experiments, we used the pTG11033 (9.6 kb, Transgene) 
which contains the firefly luciferase cDNA (under control of the strong cytomegalovirus 
immediate early, IE-CMV, promoter) and a HMG-1 intron (for enhanced transgene protein 
synthesis via increased mRNA export from the nucleus). All these pDNA were amplified in E. 
coli DH5α bacteria, extracted by alkaline lysis, and purified using the Giga Prep Plasmid 
Purification kit (Qiagen), according to the manufacturer’s protocol. They were dissolved in 
endotoxin-free water and quantified by spectrophotometry at 260 nm. Only pDNA showing a 
A260/A280 ratio between 1.8 and 2.0 were used.  
Antibacterial assays: Minimal active antibacterial concentrations, either bacteriostatic 
(MIC) or bactericidal (MBC), were determined using a liquid broth micro-dilution method, as 
previously described.[22,23] Briefly, the reagents were first diluted in water then mixed with LB 
broth inoculated with one bacterial strain, in a final volume of 200 µL per condition (i.e., 50 
µL of diluted reagent in water + 150 µL of inoculated medium), in order to test concentrations 
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ranging from 1 to 200 µм. Inoculums varied between 107 and 108 colony forming unit (CFU) 
per mL, in accordance with approved standards and previous studies.[31] After at least 24 h at 
37 °C, bacterial growth was evaluated by considering medium turbidity (absorbance 
measurements at 650 nm). In order to discriminate between bacteriostatic or bactericidal 
effects, a sample of each liquid culture was spread onto nutritive non-selective agar plates. By 
performing this at several time points of the incubation, it was possible to estimate the 
minimal exposure time and concentration that were both required to obtain a complete 
bactericidal effect.  
Combined antibacterial and transfection assays – Sequential assay: In this assay, 
lipoplexes were evaluated with regard to their abilities to kill a S. aureus strain and protect 
DNA while remaining efficient in transient transfection experiments using human bronchial 
epithelial cells. Lipoplexes were prepared by mixing the pEGFP-Luc to dilutions of cationic 
lipids, in order to form complexes characterized by increasing CR. These mixtures were kept 
at RT for 30 min then incubated with the bacterial strain RN4220 at 37 °C for 24 h. Agarose 
gel electrophoresis shift assays of lipoplexes were performed in order to evaluate the DNA 
compaction within the lipoplexes formed in each case; dextran sulfate was also used to 
recover free DNA from lipoplexes, thereby allowing assessing its integrity. Finally, lipoplexes 
were directly added dropwise into the antibiotic containing medium (EMEM) of 16HBE 14o- 
eukaryotic cells[35] that were seeded 24 h before in 96-well plates. After 24 h at 37 °C, cells 
were lysed using the Passive Lysis Buffer (Promega). For each supernatant, the luciferase 
activity was measured using the Firefly Luciferase Assay System (Promega) and the total 
protein content was quantified using the BC Assay kit (Interchim). Results were expressed as 
RLU (relative light units) per milligram of total protein. 
Combined antibacterial and transfection assays – Simultaneous assay: In this assay, 
lipoplexes were evaluated by considering their simultaneous ability to inhibit or kill a S. 
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aureus strain and to deliver a reporter pDNA into human bronchial epithelial cells. Lipoplexes 
were prepared by mixing the pGLuc to dilutions of cationic lipids, in order to form complexes 
characterized by increasing CR. These mixtures were thereafter mixed the bacterial strain 
N315 then directly added dropwise into the antibiotic free medium (EMEM) of 16HBE 14o- 
eukaryotic cells that were seeded 24 h before in 96-well plates. During 55 h, samples of the 
supernatants (5 µL each) were collected at regular time intervals in order to be assayed, as 
follows. The antibacterial activity was first estimated by considering variations of the media 
colour and further evaluated by measuring the adenylate kinase activity using the Toxilight kit 
(Lonza); results were expressed as a percentage of the maximal activity. The transfection 
efficiency was determined by evaluating the luciferase activity using the Gaussia Luciferase 
Assay System (Promega); results were expressed as RLU (relative light units) per µL. 
Animals: Six to nine weeks old female Swiss mice (Janvier breeding center) were 
housed and maintained at the University animal facility; they were processed in accordance 
with the Laboratory Animal Care Guidelines (NIH publication #85–23 revised 1985) and with 
the agreement of the regional veterinary services (authorization FR; 29–024).  
Local in vivo administration: Lipoplexes were prepared at RT by mixing, in water, 
cationic liposomes with PE-PEG5000 and pTG11033 at CR4. They were then mixed with 107 
CFU mL-1 of the bacterial strain N315. After an overnight incubation at 37 °C, the 
bactericidal effect was verified by spreading an aliquot of the mixtures onto a nutritive non 
selective agar plate. These mixtures were then administered in vivo in mice via nasal 
deposition: animals were first anesthetized via ketamin/xylazin intraperitoneal (i.p.) injection 
(40 mg kg-1 animal); next, 100 µL of complexes incorporating 70 µg of pDNA were instilled 
via the right nostril of each animal within 30 min, using a catheter (< 0.5 mm outer diameter) 
connected to a 100 µL syringe (Hamilton 1710RN) mounted on a pump (Harvard Apparatus). 
Once instilled, animals were placed in a box near a heat source until they recovered from 
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anesthesia. A total of 6 animals received 2-based lipoplexes that were previously mixed (3 
mice) or not (3 mice) with bacteria; 2 mice received 70 µg of naked (uncomplexed) pDNA. 
Systemic in vivo administration: Lipoplexes were prepared at RT by mixing, in 10% 
serum 0.9% NaCl (a medium suitable for both bacterial growth and in vivo systemic injection), 
cationic liposomes with pTG11033 at CR4. They were then mixed with 108 CFU mL-1 of the 
bacterial strain N315. After an overnight incubation at 37 °C, the bactericidal effect was 
confirmed by spreading an aliquot of the mixtures onto a nutritive non selective agar plate. 
Next, these mixtures were intravenously administered in vivo in mice. Animals were first 
placed in a restrainer and 300 µL of complexes incorporating 50 µg of pDNA were injected 
into the tail vein of each animal within 5 to 10 sec., using a ½ inch 26-gauge needle and a 1 
mL syringe. A total of 6 animals received 2-based lipoplexes that were previously mixed (3 
mice) or not (3 mice) with bacteria; 2 mice received 50 µg of naked (uncomplexed) pDNA. 
In vivo bioluminescence imaging of luciferase activity: Mice received first an i.p. 
injection of luciferin (0.16 g kg-1 animal; Interchim). Three minutes later, animals were 
anesthetized by isofluran inhalation (4% air-isofluran blend) or ketamin/xylazin i.p. injection 
(40 mg kg-1 animal). Next, animals were laid inside the acquisition chamber of an in vivo 
imaging system equipped with a cooled, slow-scan, CCD camera (NightOwl, Berthold) and 
driven with associated software (WinLight 32, Berthold). Five minutes after luciferin 
injection, luminescence images were captured at 8 x 8 binning with exposure times ranging 
from 2 to 4 min, depending on the luminescence intensity. Finally, luminescence images were 
superimposed onto still images of each mouse. Signal intensities were quantified within the 
regions of interest as photons per pixel per second. 
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Figure 1. Schematic illustration of the purpose of this study. Cationic lipids displaying 
chemical variations according to three structural parts are mixed with a luciferase (Luc) 
reporter plasmid DNA. The lipoplexes obtained are evaluated as regard their effects towards 
bacteria and eukaryotic cells incubated together. This protocol may allow distinguishing 
between at least two types of complexes: (A) lipoplexes exhibiting no or insufficient 
antibacterial effectiveness cannot prevent bacterial growth which in turn results in eukaryotic 
cell disabling. (B) On contrary, when prepared with cationic lipids incorporating suitable 
structural components, complexes could be able to achieve simultaneously, i.e. at the same 
time and in one pot, (i) biocide effect towards prokaryotic cells together with (ii) efficient and 






















3  Lipid domain: [C2:0]2 - [C14:0]2 - [C18:0]2 - [C18:1]2 - [C18:2]2
2  Spacer: P(O)C - P(S)C - P(O)N
1  Polar headgroup: N+ - P+ - As+
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Figure 2. Reaction scheme for the synthesis of cationic lipids 1, 6, 8, and 11. Reagents and 
conditions: (i) H2N(CH2)2N(CH3)2, CBrCl3, DIPEA, CH2Cl2, 0 °C for 1 h then RT for 5 h, 
85%. (ii) CH3I, CH2Cl2, reflux, O/N, 92%. (iii) H2N(CH2)2NH2, CBrCl3, DIPEA, CH2Cl2, 0 
°C for 1 h then RT for 5 h, 85%. (iv) 1H-pyrazole-1-carboxamidine hydrochloride, EtOH, 
reflux, O/N, 88%. (v) HBr.H2N(CH2)2Br, CBrCl3, DIPEA, CH2Cl2, 0 °C for 1 h then RT for 3 
h, 90% for R= C14H29 and 95% for R= C2H5. (vi) NaI, THF, reflux, O/N, 72% for R= C14H29 















Table 1. Chemical structure, numbering, and antibacterial effect of synthetic cationic lipids 
and benchmark compounds.  

































































 1 (BSV77) 1
c)




























































 13 (BSV100) >200 >200 >200 >200 nd 
Lipofectamine
®
 (Invitrogen) - >200 >200 >200 >200 >200 
DDYSA
d)
 14 200 200 200 100 75 
Ampicillin sodium salt - 1 1 100 25 >200 
Kanamycin A monosulfate - 25 10 >200 5 100 
Tetracyclin hydrochloride - 1 1 1 5 200 
 
a) see Figure S1 for the detailed chemical structure of cationic lipids; b) Sa, S. aureus; Ec, E. 
coli; Pa, P. aeruginosa; c) Susceptibilities reported as MBC in µmol per L (µм), as determined 
using the liquid broth micro-dilution assay. Bacterial inoculums ranged from 106 to 107 
colony forming unit (CFU) per mL. MBC were determined using liposomal formulations 
prepared at different times (median values, with n ≥ 3); d) DDYSA: (1,3-Dimethyl-4,5-
Dichloroimidazole-2-Ylidene)- Silver(I) Acetate. BSV, Brest Synthetic Vector; nd, not 
determined. Of note, the results obtained using PA240709 (shown here) and PA130709 (not 
shown) were very similar. 
 
  





Figure 3. Liposomes prepared with an arsonium-containing lipophosphoramide can exhibit 
potent bactericidal but also bacteriostatic effects. Different quantities of 2-based liposomes 
were diluted in LB broth inoculated with the S. aureus strain RN4220. These mixtures were 
incubated at 37 °C for several hours. At different time points, bacterial growths were assessed 
spectroscopically by measuring the absorption at 650 nm (A); samples were dotted onto a 
nutritive non-selective agar plate. After an overnight incubation at 37 °C, growths on solid 
medium (B) allowed to distinguish between either a bacteriostatic or a bactericidal effect as a 
result of the (i) exposure time with 2 and (ii) its dose in liquid broth. Of note, a bactericidal 
effect was obtained after 32 h of exposure with 20 µg mL-1 of 2 (not shown). The 6 time 
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Figure 4. Liposomes prepared with an arsonium-containing lipophosphoramide can exhibit 
biocide effects up to very high bacterial density and regardless of bacterial growth state. 
Different inoculums of the S. aureus strain RN4220 (ranging from 1010, i.e. pure O/N starved 
culture, to 103 CFU mL-1) were mixed in LB broth with increasing quantities of 2-based 
liposomes. These mixtures were then incubated at 37 °C for several hours. Plating an aliquot 
of each condition collected at three time points allowed evaluating the bacteriostatic and 
bactericidal effects of 2 according to (i) the number of bacterial cells initially present and (ii) 




No antibacterial effects evidenced
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[2-based liposomes] (µм)










































Figure 5. Lipoplexes prepared with an arsonium-containing lipophosphoramide can 
sequentially kill bacteria and then transfect eukaryotic cells in vitro. A constant amount of 
pDNA was mixed with increasing quantities of a cationic lipid (either LFM or 2) in order 
to obtain lipoplexes characterized with different charge ratios (CR). These complexes 
were then diluted in EMEM (Eagle's minimal essential medium supplemented with 10% 
serum) inoculated with the S. aureus strain RN4220. After 24 h at 37 °C, the colour of the 
culture media (indicative of its pH) was considered as a marker of bacterial growth (pink, 
neutral pH, no growth; yellow, acidic pH, growth); bacterial growths were ascertained by 
replicating an aliquot of each condition onto a nutritive non-selective LB plate (A). 
Agarose gel electrophoresis was used to assess pDNA entrapment within lipoplexes; the 
dismantling of these complexes (using dextran sulfate) allowed verifying pDNA integrity 
(B). Finally, human bronchial epithelial cells were used to evaluate the transfection 
efficiency of each mixture, in the unit of relative light units (RLU) per mg of proteins (C). 
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Figure 6. Lipoplexes prepared with an arsonium-containing lipophosphoramide can both 
inhibit bacteria and transfect eukaryotic cells in one pot. During 55 hours, 2-based lipoplexes 
(formed here at CR10) were assayed for their simultaneous ability to (1) inhibit the growth of 
the bacterial strain N315 and to (2) transfect human bronchial epithelial cells both cultivated 
in EMEM (without any antibiotics). LFM-based lipoplexes were used as controls. 
Antibacterial activity was monitored by considering the adenylate kinase (AK) activity (A) 
together with variations of the medium colour (inset in A). Transfection efficiency was 
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Figure 7. Lipoplexes prepared with an arsonium-containing lipophosphoramide can both kill 
bacteria in vitro while retaining high gene transfection efficiency in mice in vivo. 2-based 
lipoplexes (formed at CR4) were first mixed with a large inoculum (107 to 108 CFU mL-1 ) of 
the bacterial strain N315. After 12 h at 37 °C, a complete bactericidal effect was obtained (not 
shown). These mixtures were thereafter administrated in mice via intravenous (i.v.) injection 
or intranasal (i.n.) deposition in order to determine their ability to transfect the lungs and the 
nasal epithelium, respectively. Lipoplexes that were not mixed with any bacteria were used to 
determine the transfection efficiency reference level. Luciferase gene expression in mice was 
evaluated 24 h post-administration (A). Transfection efficiencies were determined via 
bioluminescence quantification within the regions of interest in the unit of ph pix-1 sec-1 (B). 
Ctrl-, negative control (mice administrated with naked DNA); Ctrl+, positive control (mice 
administrated with lipoplexes that were not incubated with bacteria); Test (mice administrated 
with lipoplexes pre-incubated with bacteria). 
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Contrary to compounds exhibiting no (Z+=N+) or 
insufficient (Z+=P+) antibacterial effectiveness, 
arsonium (Z+=As+)-containing lipophosphoramides 
can simultaneously inhibit bacteria while safely and 
efficiently delivering DNA into eukaryotic cells, 
thereby leading to luciferase (Luc) reporter gene 
expression. Such poly-functional nano-carriers may 
therefore be particularly suitable for gene therapy 
strategies under infected conditions such as within the airways of cystic fibrosis patients. 
Bacteria 
Eukaryotic cells
Z+ = As+Z+ = N+ or P+
Light
Lipophosphoramide + DNA = Lipoplex
+
Luc
Z+
